(2S)-2-aminopropanoic acid;2-fluorobenzaldehyde

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-aminopropanoic acid;2-fluorobenzaldehyde
• 化学式: C10H12FNO3
• 分子量: 213.21
• InChiKey: APKAJGQAOXVKAF-WNQIDUERSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.06
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Non-standard insulin analogues
  申请人：Case Western Reserve University

  公开号：US10995129B2

  公开（公告）日：2021-05-04

  An insulin analogue comprises an insulin A-chain polypeptide and an insulin B-chain polypeptide. The A-chain polypeptide contains a Glu substitution at a position corresponding to position A8, and an Ala, Glu, Gln, His, Tyr, Phe or Trp substitution at a position A13, relative to wild type insulin. The B-chain polypeptide contains a cyclohexanylalanine substitution at position B24, relative to wild type insulin. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.

  胰岛素类似物包括胰岛素 A 链多肽和胰岛素 B 链多肽。相对于野生型胰岛素，A 链多肽在与 A8 位置相对应的位置上含有一个 Glu 取代位，在 A13 位置上含有一个 Ala、Glu、Gln、His、Tyr、Phe 或 Trp 取代位。相对于野生型胰岛素，B 链多肽在 B24 位含有环己基丙氨酸替代物。类似物可以是哺乳动物胰岛素的类似物，如人胰岛素。还提供了编码这种胰岛素类似物的核酸。一种降低患者血糖的方法包括向患者施用生理有效量的胰岛素类似物或其生理上可接受的盐。
• SITE 2 INSULIN ANALOGUES
  申请人：Case Western Reserve University

  公开号：EP2968473A2

  公开（公告）日：2016-01-20
• [EN] SITE 2 INSULIN ANALOGUES<br/>[FR] ANALOGUES D'INSULINE DE SITE 2
  申请人：UNIV CASE WESTERN RESERVE

  公开号：WO2014145593A2

  公开（公告）日：2014-09-18

  An insulin analogue contains one or more modifications at a distinct protein surface comprising one or more of the residues at positions B13, B17, A12, A13, and/or A17. Formulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions at at least pH value in the range 6.8-8.0 either in the presence of zinc ions at a molar ratio of 2.2-10 zinc ions per six insulin analogue monomers or in the presence of fewer than 1 zinc ions per six insulin analogue monomers. Use of the above formulation in an insulin pump or insulin pump functionally integrated with a continuous glucose monitor and computer-based control algorithm as a closed-loop system. A method of treating a patient with diabetes mellitus comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient by means of intravenous, intraperitoneal, or subcutaneous injection.